Loading
A phase 2 trial of Alectinib, Entrectinib, Vemurafenib in non-small-cell lung cancer and small-cell lung cancer, run by Genentech, Inc., now recruiting.
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT04302025 by Genentech, Inc., with 99 participants planned, started 2020-11-06 and due to reach its primary completion in 2026-11-30. Interventions recorded: Alectinib, Entrectinib, Vemurafenib, Cobimetinib, Pralsetinib. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Alectinib, Entrectinib, Roche / Genentech, Small-cell lung cancer.
Shares Alectinib, Atezolizumab, Roche / Genentech, Small-cell lung cancer.
Shares Atezolizumab, Roche / Genentech, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Alectinib, Atezolizumab, Roche / Genentech, Non-small-cell lung cancer.
Shares Cobimetinib, Vemurafenib, Alectinib, Entrectinib.
Shares Resectable stage I to III non-small-cell lung cancer, Roche / Genentech, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Cobimetinib, Atezolizumab, Roche / Genentech.
Shares Cobimetinib, Vemurafenib.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/